A Study of YL202 in Patients With Advanced Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2027

Conditions

Non Small Cell Lung CancerColorectal CancerCervical CancerLocally Advanced or Metastatic Solid Tumors

Interventions

DRUG

YL202

YL202 will be intravenously infused over 60±10 min

Trial Locations (1)

Hunan Provincial Tumor Hospital, Changsha

All Listed Sponsors

lead

MediLink Therapeutics (Suzhou) Co., Ltd.

INDUSTRY